Scotia Capital Inc. acquired a new stake in Enovis Co. (NYSE:ENOV - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 13,632 shares of the company's stock, valued at approximately $598,000.
A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Aster Capital Management DIFC Ltd acquired a new position in Enovis in the 4th quarter worth about $29,000. Quadrant Capital Group LLC raised its position in Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock worth $30,000 after acquiring an additional 239 shares during the period. UMB Bank n.a. lifted its holdings in Enovis by 128.2% during the fourth quarter. UMB Bank n.a. now owns 778 shares of the company's stock valued at $34,000 after purchasing an additional 437 shares in the last quarter. Pinnacle Bancorp Inc. grew its position in shares of Enovis by 54.5% in the fourth quarter. Pinnacle Bancorp Inc. now owns 850 shares of the company's stock valued at $37,000 after purchasing an additional 300 shares during the period. Finally, FMR LLC grew its position in shares of Enovis by 20.5% in the third quarter. FMR LLC now owns 2,840 shares of the company's stock valued at $122,000 after purchasing an additional 484 shares during the period. Institutional investors and hedge funds own 98.45% of the company's stock.
Enovis Trading Up 2.4 %
Shares of Enovis stock traded up $0.75 during mid-day trading on Friday, hitting $31.91. The stock had a trading volume of 704,815 shares, compared to its average volume of 741,741. The firm has a market cap of $1.82 billion, a P/E ratio of -14.57 and a beta of 1.86. The company has a quick ratio of 1.12, a current ratio of 2.27 and a debt-to-equity ratio of 0.40. The firm has a 50-day moving average of $37.53 and a two-hundred day moving average of $42.17. Enovis Co. has a 12-month low of $29.32 and a 12-month high of $56.89.
Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported $0.98 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.92 by $0.06. The company had revenue of $560.98 million during the quarter, compared to analysts' expectations of $555.14 million. Enovis had a positive return on equity of 4.39% and a negative net margin of 5.95%. Sell-side analysts forecast that Enovis Co. will post 2.79 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Separately, Needham & Company LLC reiterated a "buy" rating and issued a $64.00 price objective on shares of Enovis in a report on Wednesday, April 9th.
Check Out Our Latest Report on Enovis
About Enovis
(
Free Report)
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Featured Stories
Before you consider Enovis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Enovis wasn't on the list.
While Enovis currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
